Palvella Therapeutics (PVLA) Shares Outstanding (Weighted Average) (2013 - 2026)

Palvella Therapeutics (PVLA) has 14 years of Shares Outstanding (Weighted Average) data on file, last reported at $13.1 million in Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $13.1 million, up 18.81% year-over-year; the trailing twelve-month figure through Mar 2026 was $13.1 million (up 18.81% YoY), and the FY2025 annual result was $11.3 million, up 405.46% from the prior year.
• Shares Outstanding (Weighted Average) grew to $13.1 million in Q1 2026 per PVLA's latest filing, from $11.3 million in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $74.4 million in Q3 2022 and troughed at $931000.0 in Q1 2023.
• A 5-year average of $21.6 million and a median of $11.0 million in 2025 frame the typical range for Shares Outstanding (Weighted Average).
• The sharpest annual moves came in 2023 and 2025: Shares Outstanding (Weighted Average) sank 98.74% in 2023, then soared 524.39% in 2025.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $74.2 million in 2022, then tumbled by 97.61% to $1.8 million in 2023, then increased by 25.75% to $2.2 million in 2024, then jumped by 405.46% to $11.3 million in 2025, then increased by 16.3% to $13.1 million in 2026.
• Business Quant data shows PVLA's Shares Outstanding (Weighted Average) at $13.1 million in Q1 2026, $11.3 million in Q4 2025, and $11.0 million in Q3 2025.